RIO DE JANEIRO-The Brazilian government has reached a tentative deal with Swiss pharmaceutical giant Roche to purchase the generic version of the AIDS drug Nelfinavir.
The South American country announced last week it would begin producing the drug in state-owned laboratories for sale January 1, 2002 because a deal had not been reached with the company. Brazil is one of the only countries in the world to guarantee treatment for all AIDS patients, including a free-of-charge program. Nelfinavir is part of the drug cocktail offered by the government for patients in need. They provided the drug to some 90,000 patients last year alone.
The Brazilian minister of health said the government was glad to have reached a deal with Roche, which will now sell the drug at a 40% reduced rate. The government will pay $35 million each year for the drug and ensure the company continued patent protection.
The Brazilian government had previously agreed to purchase other AIDS pharmaceuticals with New Jersey-based Merck after the company reduced rates of two medications by 70%.
The deal between the Brazilian government and Roche comes after 6 months of negotiations.
Brazil has the highest rate of AIDS infection in Latin America, with 210,5000 people infected.
Information from www.washingtonpost.com
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.